Atlas Salt Inc. is progressing with its Great Atlantic Salt Project in Newfoundland, aiming to become North America's first new salt mine in nearly 30 years. Construction is now permanent, and the project has secured financing interest exceeding $300 million. Positioned near a deepwater port, the mine will produce 4 million tonnes of road salt annually to reduce North America's reliance on imports for de-icing salt. This development could significantly impact the supply chain for Eastern Canadian and U.S. Northeast winter road maintenance.
Atlas Salt's Great Atlantic Salt Project is the subject, with Pluang's Basic Materials sector showing a breadth of 6 gainers against 32 decliners among 38 US stocks as of Sep 29, 2026 00:02 WIB. Sibanye Stillwater Ltd (SBSW) traded at USD 10.08, down 5.00%, contrasting with Agnico Eagle Mines Ltd (AEM) at USD 185.12, down 4.81%, and Wheaton Precious Metals Corp (WPM) at USD 136.06, down 4.80%. Typical hold times on Pluang range from 50 to 65 days for these names.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Fuel cell stocks, led by Bloom Energy, are experiencing a sharp pullback after a recent strong rally. Bloom Energy's shares fell 8% despite strong Q2 2026 revenue growth and an increased sales outlook, reflecting momentum-driven selling rather than b...
Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, suggesting a 28% upside from its current price of around $85. The stock shows strong momentum, trading well above its 50-day and 200-day moving averages. How...
